Arcellx (ACLX) Interest Expenses (2022 - 2025)
Arcellx (ACLX) recorded quarterly Interest Expenses of -$12000.0 in Q4 2025, down 200.0% quarter-over-quarter from $12000.0 in Q1 2025, and down 271.43% on a YoY basis from $7000.0 in Q4 2024.
Arcellx (ACLX) Interest Expenses (2022 - 2025) Analysis & Trends
Arcellx's Interest Expenses history runs 4 years deep, the most recent figure standing at -$12000.0 for Q4 2025.
- In Q4 2025, Interest Expenses fell 271.43% year-over-year to -$12000.0; the TTM figure through Sep 2025 stood at $19000.0 (down 99.05% YoY), while the FY2024 annual figure was $1.0 million, down 73.19% from the prior year.
- Interest Expenses was -$12000.0 for Q4 2025 at Arcellx, down from $12000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.1 million in Q4 2022 to a low of -$12000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $470785.7 across 4 years, with a median of $454500.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 29233.33% in 2023, then plunged 271.43% in 2025.
- A 4-year view of Interest Expenses shows it stood at $1.1 million in 2022, then retreated by 12.46% to $977000.0 in 2023, then sank by 99.28% to $7000.0 in 2024, then slumped by 271.43% to -$12000.0 in 2025.
- The last three Interest Expenses figures came in at -$12000.0 (Q4 2025), $12000.0 (Q1 2025), and $7000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Sep 30, 2024 | 114,000.00 |
| Jun 30, 2024 | 321,000.00 |
| Jun 30, 2024 | 321,000.00 |
| Mar 31, 2024 | 588,000.00 |
| Mar 31, 2024 | 588,000.00 |
| Dec 31, 2023 | 977,000.00 |
| Dec 31, 2023 | 977,000.00 |
| Sep 30, 2023 | 959,000.00 |
| Sep 30, 2023 | 959,000.00 |
| Jun 30, 2023 | 880,000.00 |
| Jun 30, 2023 | 880,000.00 |
| Mar 31, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.03 Mn |